Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients-Review and Perspectives.

ABSTRACT: Seventy percent of all breast cancer subtypes are hormone receptor-positive. Adjuvant endocrine therapy in these patients plays a key role. Despite the traditional duration of a 5-year intake, the risk of relapse remains elevated in a substantial proportion of patients. Several trials report that the risk of late recurrence is reduced by the extension of adjuvant endocrine therapy beyond 5 years. However, the optimal duration of endocrine therapy is still a matter of debate. The newer data only show a marginal benefit resulting from extension beyond 7 to 10 years. Furthermore, extension may be associated with more side effects. Thus, the adequate selection of patients qualifying for an extended adjuvant therapy is of importance. Tools/genomic tests, which include the characteristics of the

SUBMITTER: Bekes I 

PROVIDER: S-EPMC10453164 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature